{
    "hands_on_practices": [
        {
            "introduction": "A fundamental step in clinical research is to accurately quantify the scope of a health issue within a population. This involves using precise epidemiological measures to describe disease frequency. This practice introduces two of the most essential metrics: point prevalence, which provides a snapshot of existing cases at a specific moment, and cumulative incidence, which measures the risk of developing a new condition over a period. Mastering the calculation and distinction between these two concepts is crucial for understanding a disease's burden and tracking its progression over time. ",
            "id": "4983937",
            "problem": "A university health center conducts a prospective cohort study to quantify burden and risk of a seasonal respiratory infection in an undergraduate dormitory, as part of applying the scientific method in clinical research. At baseline (day $0$), a census of $N = 1000$ students is performed with clinical assessment and laboratory confirmation to determine who currently has active infection. Exactly $50$ students have active infection at baseline. The remaining students are free of active infection at baseline. The cohort is then followed for $6$ months with complete case ascertainment and no loss to follow-up; during this interval, exactly $220$ new, laboratory-confirmed infections occur among those who were free of active infection at baseline.\n\nFormally define point prevalence and cumulative incidence in words suitable for a clinical research report, making explicit the population and time reference in each definition. Then, using only foundational definitions as your starting point, compute:\n- the point prevalence of active infection at baseline, and\n- the $6$-month cumulative incidence of infection among those at risk at baseline.\n\nExpress both answers as decimals, rounded to four significant figures. Do not use percentage signs. No units are required for these proportions.",
            "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. It provides a standard epidemiological scenario with all necessary data to compute the requested metrics. The problem is therefore deemed valid.\n\nThe solution proceeds first by formally defining the requested epidemiological measures—point prevalence and cumulative incidence—in the specific context of the study, and then by calculating their values based on the provided data.\n\n**Formal Definitions**\n\nPoint Prevalence: In clinical research, point prevalence measures the proportion of a population that has a specific disease or condition at a single, specified point in time. For the described study, the point prevalence at baseline is formally defined as the number of students with a laboratory-confirmed active respiratory infection on day $0$, divided by the total number of students in the dormitory census on day $0$.\n\nCumulative Incidence: Cumulative incidence, also referred to as incidence proportion or risk, quantifies the proportion of an initially disease-free population (the population at risk) that develops a specific disease or condition over a specified period of observation. For this study, the $6$-month cumulative incidence is formally defined as the number of new laboratory-confirmed respiratory infections that occurred during the $6$-month follow-up period, divided by the number of students who were free of infection and therefore at risk at the beginning of the period (day $0$).\n\n**Calculations**\n\nLet $N$ represent the total population size of the student dormitory at baseline (day $0$), where $N=1000$.\nLet $C_{prev}$ represent the number of existing (prevalent) cases of active infection at baseline, where $C_{prev}=50$.\nLet $C_{inc}$ represent the number of new (incident) cases of infection that occurred during the $6$-month follow-up period, where $C_{inc}=220$.\n\n**1. Point Prevalence at Baseline**\n\nThe point prevalence, denoted as $P$, is calculated using its fundamental definition:\n$$P = \\frac{\\text{Number of existing cases at a point in time}}{\\text{Total population at that same point in time}}$$\nSubstituting the given values:\n$$P = \\frac{C_{prev}}{N} = \\frac{50}{1000} = 0.05$$\nThe problem requires the answer to be expressed to four significant figures. To express $0.05$ with four significant figures, we add trailing zeros, which are significant in this context.\n$$P = 0.0500$$\n\n**2. 6-Month Cumulative Incidence**\n\nThe cumulative incidence, denoted as $CI$, is calculated using its fundamental definition:\n$$CI = \\frac{\\text{Number of new cases over a specified period}}{\\text{Number of individuals at risk at the start of the period}}$$\nFirst, we must determine the population at risk, $N_{risk}$, at baseline. This is the total population minus those who already have the infection, as they are not at risk of developing a *new* infection.\n$$N_{risk} = N - C_{prev} = 1000 - 50 = 950$$\nNow, we can calculate the $6$-month cumulative incidence using the number of new cases, $C_{inc} = 220$, that occurred within this at-risk population.\n$$CI = \\frac{C_{inc}}{N_{risk}} = \\frac{220}{950}$$\nPerforming the division gives:\n$$CI = \\frac{22}{95} \\approx 0.231578947...$$\nRounding this value to four significant figures, we examine the fifth significant digit. Since the fifth digit ($7$) is $5$ or greater, we round up the fourth significant digit.\n$$CI \\approx 0.2316$$\n\nThe final answers for point prevalence and $6$-month cumulative incidence, respectively, are $0.0500$ and $0.2316$. These will be presented in a row matrix as requested.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.0500 & 0.2316 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Once a health problem is described, the scientific method guides us in evaluating potential interventions. The Randomized Controlled Trial (RCT) is the cornerstone for determining if a new treatment is effective, but its results can be expressed in several ways. This exercise challenges you to calculate and interpret the most common measures of treatment effect: absolute risk, risk difference, risk ratio, and odds ratio. Understanding how each metric is derived and what it uniquely communicates is a critical skill for appraising clinical literature and translating trial results into meaningful clinical practice. ",
            "id": "4984045",
            "problem": "A pharmaceutical company conducts a parallel-group Randomized Controlled Trial (RCT) to test whether a new antihypertensive drug reduces the $1$-year risk of stroke compared with standard care. A total of $2400$ participants with hypertension are randomized equally: $1200$ to the new drug and $1200$ to standard care. Over $1$ year, there are $48$ strokes in the new drug arm and $84$ strokes in the standard care arm. Using only foundational definitions of probability (risk as the proportion of individuals with the event in a group, odds as the ratio of the probability of the event to the probability of no event) and the idea that comparisons can be made by differences or ratios, determine which option correctly computes and interprets the following for this trial: absolute risk in each arm, risk difference (treatment minus control), risk ratio, and odds ratio.\n\nChoose the single best option that correctly reports the numerical values and provides clinically sound interpretations of each metric in this randomized clinical context.\n\nA. New drug absolute risk $= 48/1200 = 0.04 = 4\\%$; standard care absolute risk $= 84/1200 = 0.07 = 7\\%$; risk difference (treatment minus control) $= 0.04 - 0.07 = -0.03$, that is an absolute risk reduction of $3$ percentage points (about $3$ fewer strokes per $100$ treated over $1$ year); risk ratio $= 0.04/0.07 \\approx 0.57$, meaning the probability of stroke is about $43\\%$ lower with the new drug; odds ratio $= (48/1152)/(84/1116) \\approx 0.55$, meaning the odds of stroke are about $45\\%$ lower with the new drug, which is numerically close to the risk ratio here because the event is uncommon.\n\nB. New drug absolute risk $= 4\\%$; standard care absolute risk $= 7\\%$; risk difference (treatment minus control) $= +3$ percentage points, indicating an absolute risk increase of $3\\%$; risk ratio $= 0.57$, indicating a $43$ percentage point reduction; odds ratio $= 0.57$, exactly equal to and interchangeable with the risk ratio in all cases.\n\nC. New drug absolute risk $= 48/1152 \\approx 4.17\\%$; standard care absolute risk $= 84/1116 \\approx 7.53\\%$; risk difference $= 4.17\\% - 7.53\\% \\approx -3.36$ percentage points; risk ratio $= 4.17\\%/7.53\\% \\approx 0.55$; odds ratio $= 0.04/0.07 \\approx 0.57$. The denominators should exclude those with events so that the risk uses non-events.\n\nD. New drug absolute risk $= 4\\%$; standard care absolute risk $= 7\\%$; risk difference (treatment minus control) $= -3$ percentage points; risk ratio $= 7\\%/4\\% = 1.75$, indicating a $75\\%$ higher risk on the new drug; odds ratio $= (48/1200)/(84/1200) = 48/84 \\approx 0.57$.\n\nE. New drug absolute risk $= 4\\%$; standard care absolute risk $= 7\\%$; risk difference $= -0.03$, interpreted as $0.03$ fewer strokes per $1000$ treated; risk ratio $= 0.57$, interpreted as an exact $43\\%$ absolute reduction in risk; odds ratio $= (48 \\times 1116)/(84 \\times 1152) \\approx 0.55$, which means $45\\%$ fewer strokes per $100$ patients, not just fewer odds.",
            "solution": "The problem statement describes a parallel-group Randomized Controlled Trial (RCT) and asks for the calculation and interpretation of several epidemiological measures of association and effect.\n\n### Step 1: Extract Givens\n-   **Study Design:** Parallel-group Randomized Controlled Trial\n-   **Intervention Group (New Drug):** Number of participants, $N_T = 1200$. Number of events (strokes), $E_T = 48$.\n-   **Control Group (Standard Care):** Number of participants, $N_C = 1200$. Number of events (strokes), $E_C = 84$.\n-   **Follow-up Period:** $1$ year.\n-   **Provided Definitions:**\n    -   **Risk:** Proportion of individuals with the event in a group.\n    -   **Odds:** Ratio of the probability of the event to the probability of no event.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is scientifically grounded, well-posed, and objective. It describes a standard, realistic clinical trial scenario. The provided data are complete, consistent, and sufficient for calculating the required metrics (absolute risk, risk difference, risk ratio, and odds ratio). The terminology and definitions are standard in epidemiology and clinical research. There are no contradictions, ambiguities, or scientific flaws.\n\n**Verdict:** The problem is valid.\n\n### Step 3: Derivation of Metrics\nBased on the givens and definitions, we can derive the required values.\n\n**1. Absolute Risk (AR)**\nThe absolute risk, or incidence proportion, is defined as the number of new cases (events) divided by the total number of individuals in the group at the start of the follow-up.\n\n-   **Absolute Risk in the Treatment Arm ($AR_T$):**\n    $$AR_T = \\frac{E_T}{N_T} = \\frac{48}{1200} = \\frac{4}{100} = 0.04$$\n    Expressed as a percentage, this is $0.04 \\times 100\\% = 4\\%$.\n\n-   **Absolute Risk in the Control Arm ($AR_C$):**\n    $$AR_C = \\frac{E_C}{N_C} = \\frac{84}{1200} = \\frac{7}{100} = 0.07$$\n    Expressed as a percentage, this is $0.07 \\times 100\\% = 7\\%$.\n\n**2. Risk Difference (RD)**\nThe problem asks for the risk difference, specified as \"treatment minus control\". This is also known as the Absolute Risk Reduction (ARR) when the value is positive, or simply the risk difference.\n$$RD = AR_T - AR_C = 0.04 - 0.07 = -0.03$$\nA negative value indicates a reduction in risk in the treatment group. The magnitude, $0.03$, corresponds to an absolute risk reduction of $3$ percentage points. This means for every $100$ people treated with the new drug for $1$ year, there are $3$ fewer strokes compared to standard care.\n\n**3. Risk Ratio (RR)**\nThe risk ratio is the ratio of the risk in the treatment arm to the risk in the control arm.\n$$RR = \\frac{AR_T}{AR_C} = \\frac{0.04}{0.07} = \\frac{4}{7} \\approx 0.5714$$\nThe relative risk reduction (RRR) is given by $1 - RR$.\n$$RRR = 1 - \\frac{4}{7} = \\frac{3}{7} \\approx 0.4286$$\nThis means the new drug reduces the risk of stroke by approximately $42.9\\%$ (or about $43\\%$) relative to the risk with standard care.\n\n**4. Odds Ratio (OR)**\nThe odds of an event are the ratio of the probability of the event occurring to the probability of it not occurring.\n-   **Number of non-events in the Treatment Arm:** $NonE_T = N_T - E_T = 1200 - 48 = 1152$.\n-   **Number of non-events in the Control Arm:** $NonE_C = N_C - E_C = 1200 - 84 = 1116$.\n\n-   **Odds in the Treatment Arm ($Odds_T$):**\n    $$Odds_T = \\frac{E_T}{NonE_T} = \\frac{48}{1152}$$\n\n-   **Odds in the Control Arm ($Odds_C$):**\n    $$Odds_C = \\frac{E_C}{NonE_C} = \\frac{84}{1116}$$\n\n-   The Odds Ratio is the ratio of these odds:\n    $$OR = \\frac{Odds_T}{Odds_C} = \\frac{48/1152}{84/1116} = \\frac{48 \\times 1116}{84 \\times 1152}$$\n    Simplifying the expression:\n    $$OR = \\frac{(4 \\times 12) \\times (93 \\times 12)}{(7 \\times 12) \\times (96 \\times 12)} = \\frac{4 \\times 93}{7 \\times 96} = \\frac{372}{672} = \\frac{31}{56} \\approx 0.5536$$\nThe reduction in odds is $1 - OR \\approx 1 - 0.5536 = 0.4464$, or about $45\\%$.\nAs expected for a low-probability event (risks of $4\\%$ and $7\\%$), the odds ratio ($OR \\approx 0.55$) is numerically close to, but slightly more extreme (further from $1$) than, the risk ratio ($RR \\approx 0.57$).\n\n### Step 4: Option-by-Option Analysis\nWe now evaluate each option against these correct derivations.\n\n**A. New drug absolute risk $= 48/1200 = 0.04 = 4\\%$; standard care absolute risk $= 84/1200 = 0.07 = 7\\%$; risk difference (treatment minus control) $= 0.04 - 0.07 = -0.03$, that is an absolute risk reduction of $3$ percentage points (about $3$ fewer strokes per $100$ treated over $1$ year); risk ratio $= 0.04/0.07 \\approx 0.57$, meaning the probability of stroke is about $43\\%$ lower with the new drug; odds ratio $= (48/1152)/(84/1116) \\approx 0.55$, meaning the odds of stroke are about $45\\%$ lower with the new drug, which is numerically close to the risk ratio here because the event is uncommon.**\n-   **AR Calculation:** Correct.\n-   **RD Calculation and Interpretation:** Correct.\n-   **RR Calculation and Interpretation:** Correct, including the correct calculation of relative risk reduction.\n-   **OR Calculation and Interpretation:** Correct, including the correct formula, calculation, and explanation for its proximity to the risk ratio.\n-   **Verdict:** **Correct**. This option accurately presents all calculations and provides clinically sound and precise interpretations.\n\n**B. New drug absolute risk $= 4\\%$; standard care absolute risk $= 7\\%$; risk difference (treatment minus control) $= +3$ percentage points, indicating an absolute risk increase of $3\\%$; risk ratio $= 0.57$, indicating a $43$ percentage point reduction; odds ratio $= 0.57$, exactly equal to and interchangeable with the risk ratio in all cases.**\n-   **RD Calculation and Interpretation:** The sign is incorrect ($RD = -0.03$, not $+0.03$). Thus, it is a risk reduction, not an increase.\n-   **RR Interpretation:** The relative risk reduction is $43\\%$, not $43$ percentage points. This confuses relative and absolute measures.\n-   **OR Calculation and Interpretation:** The value is incorrect ($OR \\approx 0.55$, not $0.57$), and the statement that OR and RR are \"exactly equal and interchangeable in all cases\" is a significant conceptual error.\n-   **Verdict:** **Incorrect**.\n\n**C. New drug absolute risk $= 48/1152 \\approx 4.17\\%$; standard care absolute risk $= 84/1116 \\approx 7.53\\%$; risk difference $= 4.17\\% - 7.53\\% \\approx -3.36$ percentage points; risk ratio $= 4.17\\%/7.53\\% \\approx 0.55$; odds ratio $= 0.04/0.07 \\approx 0.57$. The denominators should exclude those with events so that the risk uses non-events.**\n-   **AR Calculation:** Fundamentally incorrect. The calculation shown, $E/(N-E)$, is the formula for odds, not risk. The definition of risk uses the total population $N$ as the denominator.\n-   **RR and OR Calculation:** Because it incorrectly calculates risk, it subsequently mislabels the odds ratio as the risk ratio and the risk ratio as the odds ratio.\n-   **Verdict:** **Incorrect**.\n\n**D. New drug absolute risk $= 4\\%$; standard care absolute risk $= 7\\%$; risk difference (treatment minus control) $= -3$ percentage points; risk ratio $= 7\\%/4\\% = 1.75$, indicating a $75\\%$ higher risk on the new drug; odds ratio $= (48/1200)/(84/1200) = 48/84 \\approx 0.57$.**\n-   **RR Calculation:** It calculates $AR_C/AR_T$ instead of $AR_T/AR_C$. The interpretation is also flawed; an RR of $1.75$ would imply a higher risk in the group represented by the numerator (standard care), not the new drug.\n-   **OR Calculation:** The formula presented, $(E_T/N_T)/(E_C/N_C)$, is the formula for the risk ratio, not the odds ratio.\n-   **Verdict:** **Incorrect**.\n\n**E. New drug absolute risk $= 4\\%$; standard care absolute risk $= 7\\%$; risk difference $= -0.03$, interpreted as $0.03$ fewer strokes per $1000$ treated; risk ratio $= 0.57$, interpreted as an exact $43\\%$ absolute reduction in risk; odds ratio $= (48 \\times 1116)/(84 \\times 1152) \\approx 0.55$, which means $45\\%$ fewer strokes per $100$ patients, not just fewer odds.**\n-   **RD Interpretation:** Incorrect. A difference of $0.03$ corresponds to $3$ fewer strokes per $100$ people, or $30$ per $1000$.\n-   **RR Interpretation:** Incorrect. The reduction is a *relative* reduction, not *absolute*. Also, it is an approximation ($4/7$), not \"exact\".\n-   **OR Interpretation:** Incorrect. The odds ratio describes the relative change in *odds*, not a direct change in the number of events per $100$ patients. Interpreting a $45\\%$ reduction in odds as a $45\\%$ reduction in strokes is a common but serious misinterpretation.\n-   **Verdict:** **Incorrect**.\n\nBased on this comprehensive analysis, option A is the only one that is entirely correct in its calculations and interpretations.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Effective clinical research and practice depend on reliable tools for identifying disease. When a new diagnostic test is developed, it must undergo rigorous evaluation to determine its accuracy. This hands-on practice walks you through the standard method for assessing a new test against a \"gold standard,\" using the core statistical concepts of sensitivity, specificity, and predictive values. By working directly with hypothetical study data, you will learn to construct a $2 \\times 2$ table and compute these key performance indicators, gaining insight into how we decide whether a test is fit for clinical use. ",
            "id": "4984023",
            "problem": "A hospital laboratory evaluates a new point-of-care rapid antigen test for detecting a respiratory pathogen by comparing it to a gold-standard polymerase chain reaction (PCR) assay. As part of a cross-sectional diagnostic accuracy study designed according to the scientific method (formulate the question, collect data under controlled conditions, and analyze using established probability definitions), the following $2 \\times 2$ classification counts were observed among $480$ consecutively enrolled adult patients:\n\n- Of the $120$ patients who were disease-positive according to PCR, the rapid test was positive in $102$ and negative in $18$.\n- Of the $360$ patients who were disease-negative according to PCR, the rapid test was positive in $54$ and negative in $306$.\n\nUsing the foundational definitions of conditional probability and Bayes' theorem, do the following:\n\n1. Define sensitivity, specificity, positive predictive value, and negative predictive value conceptually in terms of conditional probabilities that relate test results to true disease status.\n2. Derive expressions for these quantities starting from the definitions in task $1$ and compute their values from the observed counts.\n3. Using the derived values and the concept of diagnostic odds, compute the Diagnostic Odds Ratio (DOR) for the rapid test.\n\nProvide only the Diagnostic Odds Ratio as your final reported value. Round your final answer to four significant figures. Express the final answer as a pure number without any unit or percent sign.",
            "solution": "The problem presents a standard scenario for the evaluation of a diagnostic test against a gold standard, providing all necessary data in a consistent and complete manner. The problem is scientifically grounded in the principles of biostatistics and epidemiology, well-posed, and objective. It is therefore deemed valid for a full analytical solution.\n\nLet $D^+$ be the event that a patient has the disease (is positive according to the gold-standard PCR assay), and $D^-$ be the event that a patient does not have the disease. Let $T^+$ be the event that the new rapid test is positive, and $T^-$ be the event that the new rapid test is negative.\n\nFrom the problem statement, we can populate a $2 \\times 2$ contingency table with the following counts:\n- True Positives ($TP$): Patients with the disease who test positive. $TP = 102$.\n- False Negatives ($FN$): Patients with the disease who test negative. $FN = 18$.\n- False Positives ($FP$): Patients without the disease who test positive. $FP = 54$.\n- True Negatives ($TN$): Patients without the disease who test negative. $TN = 306$.\n\nWe can verify the given marginal totals:\n- Total disease-positive patients: $TP + FN = 102 + 18 = 120$.\n- Total disease-negative patients: $FP + TN = 54 + 306 = 360$.\n- Total patients in the study: $120 + 360 = 480$.\nThe data are internally consistent.\n\n**1. Conceptual Definitions of Diagnostic Metrics**\n\nThe primary measures of a diagnostic test's accuracy are defined in terms of conditional probabilities, which relate the test result to the true disease status.\n\n- **Sensitivity ($Sens$)**: The probability that the test correctly identifies a patient who has the disease. It is the conditional probability of a positive test result ($T^+$) given that the disease is present ($D^+$).\n$$Sens = P(T^+ | D^+)$$\n\n- **Specificity ($Spec$)**: The probability that the test correctly identifies a patient who does not have the disease. It is the conditional probability of a negative test result ($T^-$) given that the disease is absent ($D^-$).\n$$Spec = P(T^- | D^-)$$\n\n- **Positive Predictive Value ($PPV$)**: The probability that a patient with a positive test result actually has the disease. It is the conditional probability of the disease being present ($D^+$) given a positive test result ($T^+$).\n$$PPV = P(D^+ | T^+)$$\n\n- **Negative Predictive Value ($NPV$)**: The probability that a patient with a negative test result actually does not have the disease. It is the conditional probability of the disease being absent ($D^-$) given a negative test result ($T^-$).\n$$NPV = P(D^- | T^-)$$\n\n**2. Derivation of Expressions and Computation of Values**\n\nThese probabilities are estimated from the observed counts in the sample.\n\n- **Sensitivity**:\n$$Sens = \\frac{\\text{Number of True Positives}}{\\text{Total Number with Disease}} = \\frac{TP}{TP + FN}$$\n$$Sens = \\frac{102}{102 + 18} = \\frac{102}{120} = 0.85$$\n\n- **Specificity**:\n$$Spec = \\frac{\\text{Number of True Negatives}}{\\text{Total Number without Disease}} = \\frac{TN}{FP + TN}$$\n$$Spec = \\frac{306}{54 + 306} = \\frac{306}{360} = 0.85$$\n\n- **Positive Predictive Value**:\n$$PPV = \\frac{\\text{Number of True Positives}}{\\text{Total Number with Positive Test}} = \\frac{TP}{TP + FP}$$\n$$PPV = \\frac{102}{102 + 54} = \\frac{102}{156} \\approx 0.6538$$\n\n- **Negative Predictive Value**:\n$$NPV = \\frac{\\text{Number of True Negatives}}{\\text{Total Number with Negative Test}} = \\frac{TN}{FN + TN}$$\n$$NPV = \\frac{306}{18 + 306} = \\frac{306}{324} \\approx 0.9444$$\n\n**3. Computation of the Diagnostic Odds Ratio (DOR)**\n\nThe Diagnostic Odds Ratio ($DOR$) is a single summary statistic of test performance that is independent of disease prevalence. It is defined as the ratio of the odds of positivity in the diseased group to the odds of positivity in the non-diseased group.\n\nThe odds of a positive test in the diseased group are given by:\n$$\\text{Odds}(T^+|D^+) = \\frac{P(T^+|D^+)}{P(T^-|D^+)} = \\frac{P(T^+|D^+)}{1 - P(T^+|D^+)} = \\frac{Sens}{1 - Sens}$$\n\nThe odds of a positive test in the non-diseased group are given by:\n$$\\text{Odds}(T^+|D^-) = \\frac{P(T^+|D^-)}{P(T^-|D^-)} = \\frac{1 - P(T^-|D^-)}{P(T^-|D^-)} = \\frac{1 - Spec}{Spec}$$\n\nThe $DOR$ is the ratio of these two odds:\n$$DOR = \\frac{\\text{Odds}(T^+|D^+)}{\\text{Odds}(T^+|D^-)} = \\frac{Sens / (1 - Sens)}{(1 - Spec) / Spec}$$\n\nAn equivalent and more direct formula for the $DOR$ can be derived using the counts from the contingency table:\n$$DOR = \\frac{\\frac{TP}{TP+FN} / \\frac{FN}{TP+FN}}{\\frac{FP}{FP+TN} / \\frac{TN}{FP+TN}} = \\frac{TP / FN}{FP / TN} = \\frac{TP \\times TN}{FP \\times FN}$$\n\nUsing the given values:\n$TP = 102$\n$TN = 306$\n$FP = 54$\n$FN = 18$\n\nWe substitute these values into the formula:\n$$DOR = \\frac{102 \\times 306}{54 \\times 18} = \\frac{31212}{972} \\approx 32.1111...$$\n\nThe problem requires the final answer to be rounded to four significant figures.\n$$DOR \\approx 32.11$$",
            "answer": "$$\\boxed{32.11}$$"
        }
    ]
}